Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Change in Cash (2016 - 2025)

Historic Change in Cash for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$9.3 million.

  • Sangamo Therapeutics' Change in Cash fell 17213.32% to -$9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.2 million, marking a year-over-year increase of 4124.07%. This contributed to the annual value of -$3.3 million for FY2024, which is 9405.14% up from last year.
  • Sangamo Therapeutics' Change in Cash amounted to -$9.3 million in Q3 2025, which was down 17213.32% from $13.2 million recorded in Q2 2025.
  • Sangamo Therapeutics' Change in Cash's 5-year high stood at $46.9 million during Q2 2021, with a 5-year trough of -$58.6 million in Q1 2022.
  • For the 5-year period, Sangamo Therapeutics' Change in Cash averaged around -$5.4 million, with its median value being -$8.4 million (2021).
  • In the last 5 years, Sangamo Therapeutics' Change in Cash plummeted by 60163.99% in 2022 and then soared by 22519.39% in 2024.
  • Sangamo Therapeutics' Change in Cash (Quarter) stood at $1.9 million in 2021, then skyrocketed by 206.26% to $5.9 million in 2022, then plummeted by 292.54% to -$11.3 million in 2023, then surged by 124.02% to $2.7 million in 2024, then crashed by 442.88% to -$9.3 million in 2025.
  • Its Change in Cash stands at -$9.3 million for Q3 2025, versus $13.2 million for Q2 2025 and -$16.7 million for Q1 2025.